Topically applied tissue factor pathway inhibitor reduced intimai thickness of small arterial autografts in rabbits

Journal of Vascular Surgery

Volumn 34, Issue 1, 2001, Pages 151-155

  Sun, Ling Bo ^a   Utoh, Junichi ^b   Moriyama, Shuji ^b   Tagami, Hirofumi ^b   Okamoto, Ken ^b   Kitamura, Nobuo ^b  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; LIPOPROTEIN; LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR; TISSUE FACTOR PATHWAY INHIBITOR;

ANIMAL; ARTICLE; AUTOTRANSPLANTATION; DRUG EFFECT; FEMORAL ARTERY; IMAGE PROCESSING; IMMUNOHISTOCHEMISTRY; INTIMA; MALE; PATHOLOGY; RABBIT; TOPICAL DRUG ADMINISTRATION; TRANSPLANTATION; VASCULAR PATENCY;

ADMINISTRATION, TOPICAL; ANIMALS; ANTICOAGULANTS; FEMORAL ARTERY; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; LIPOPROTEINS; MALE; RABBITS; TRANSPLANTATION, AUTOLOGOUS; TUNICA INTIMA; VASCULAR PATENCY;

EID: 0035409261     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1067/mva.2001.113307     Document Type: Article

References (32)

1. Cooley BC, Gould JS. Topically applied antithrombotic agents offer a new therapeutic approach to the prevention of microvascular thrombosis. Microsurgery 1991;12:281-7.
2. Liu MW, Roubin G, King SB III. Restenosis after coronary angioplasty: potential biologic determinants and role of intimal hyperplasia. Circulation 1989;79:1374-87.
3. Davies MG, Hagen PO. Pathobiology of intimal hyperplasia. Br J Surg 1994;81;1254-69.
4. Unterberg C, Sandrock D, Nebendahl K, Buchwald AB. Reduced acute thrombus formation results in decreased neointimal proliferation after coronary angioplasty. J Am Coll Cardiol 1995;26:1747-54.
5. Abendschein DR, Recchia D, Meng YY, Oltrona L, Wickline SA, Eisenberg PR. Inhibition of thrombin attenuates stenosis after arterial injury in minipigs. J Am Coll Cardiol 1996;28;1849-55.
6. Ellis SG, Roubin GS, Wilentz J, Douglas JS, King SB III. Effect of 18-to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. Am Heart J 1989;117:777-82.
7. Serruys PW, Herrman JP, Simon R, Rutsch W, Bode C, Laarman GJ, et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty: Helvetica Investigators. N Engl J Med 1995;333:757-63.
8. Antmen EM, for the TIMI 9A Investigators. Hirudin in acute myocardial infarction: safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial. Circulation 1994;90:1624-30.
9. Braze GJ Jr. Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med 1995;46:103-12.
10. Lindahl AK. Tissue factor pathway inhibitor: from unknown coagulation inhibitor to major antithrombotic principle. Cardiovasc Res 1997;33:286-91.
11. Khouri RK, Koudsi B, Kaiding F, Qrnberg RL, Wun TC. Prevention of thrombosis by topical application of tissue factor pathway inhibitor in a rabbit model of vascular trauma. Ann Plast Surg 1993;30: 398-402.
12. Lantieri LA, Ozbek MR, Deune EG, Ornberg RL, Brown DM, Chung SH, et al. Prevention of microvascular thrombosis by topical application of recombinant tissue factor pathway inhibitor. Plast Resconstr Surg 1996;97:587-94.
13. Rapp JH, Pan XM, Ghermay A, Gazetas P, Brady SE, Reilly LM. A blinded trial of local recombinant tissue factor pathway inhibitor versus either local or systemic heparin in a vein bypass model. J Vasc Surg 1997;25:726-9.
14. Jang Y, Guzman LA, Lincoff AM, Gottsauner-Wolf M, Forudi F, Hart CE, et al. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation 1995;92:3041-50.
15. Brown DM, Kania NM, Choi ET, Lantieri LA, Pasia EN, Wun TC, et al. Local irrigation with tissue factor pathway inhibitor inhibits intimal hyperplasia induced by arterial interventions. Arch Surg 1996;131: 1086-90.
16. Oltrona L, Speidel CM, Recchia D, Wickline SA, Eisenberg PR, Abendschein DR. Inhibition of tissue factor-mediated coagulation markedly attenuates stenosis after balloon-induced arterial injury in minipigs. Circulation 1997;96:646-52.
17. Sun LB, Goto H, Utoh J, Tsurusaki S, Hamuro T, Kamikubo Y, et al. Antithrombogenic effects of topically applied tissue factor pathway inhibitor (TFPI) in a rabbit model of traumatized arterial autografts: a preliminary report. Kumamoto Medical Journal 1998;46:7-11.
18. Kamikubo Y, Hamuro T, Matsuda J, Shinya N, Miyamoto S, Funatsu A, et al. Antithrombotic effect of human recombinant tissue factor pathway inhibitor on endotoxin-induced intravascular coagulation in rats: concerted effect with antithrombin. Thromb Haemost 1996; 76:621-6.
19. Clowes AW, Reidy MA. Prevention of stenosis after vascular reconstruction: pharmacologic control of intimal hyperplasia - a review. J Vasc Surg 1991;13:885-91.
20. Dumanian GA, Heil BV, Khouri RK, Hong C, Labadie K, Wun TC, et al. Tissue factor and its inhibition at the human microvascular anastomosis, J Surg Res 1996;60:263-9.
21. Chen LB, Buchanan JM. Mitogenic activity of blood components - I: thrombin and prothrombin. Proc Natl Acad Sci U S A 1975;72:131-5.
22. Bar-Shavit R, Benezra M, Eldor A, Hy-Am E, Fenton JW II, Wilner GD, et al. Thrombin immobilized to extracellular matrix is a potent mitogen for vascular smooth muscle cells: nonenzymatic mode of action. Cell Regul 1990;1:453-63.
23. Graham DJ, Alexander JJ. The effects of thrombin on bovine aortic endothelial and smooth muscle cells. J Vasc Surg 1990;11:307-12.
24. Johnson PC, Heil BV, Parva B, Hong C, Labadie K, Brezniak DV, et al. Thrombin activity on dissected and anastomosed human arteries. J Surg Res 1996;60:193-8.
25. Gasic GP, Arenas CP, Gasic TB, Gasic GJ. Coagulation factors X, Xa, and protein S as potent mitogens of cultured aortic smooth muscle cells. Proc Natl Acad Sci U S A 1992;89:2317-20.
26. Ko FN, Yang YC, Huang SC, Ou JT. Coagulation factor Xa stimulates platelet-derived growth factor release and mitogenesis in cultured vascular smooth muscle cells of rat. J Clin Invest 1996;98:1493-501.
27. Han X, Girard TJ, Baum P, Abendschein DR, Broze GJ Jr. Structural requirements for TFPI-mediated inhibition of neointimal thickening after balloon injury in the rat. Arterioscler Thromb Vasc Biol 1999;19: 2567-7.
28. Kamikubo Y, Nakahara Y, Takemoto S, Hamuro T, Miyamoto S, Funatsu A. Human recombinant tissue-factor pathway inhibitor prevents the proliferation of cultured human neonatal aortic smooth muscle cells. FEBS Lett 1997;407:116-20.
29. Acland RD, Anderson G, Siemionow M, McCabe S. Direct in vivo observations of embolic events in the microcirculation distal to a small-vessel anastomosis. Plast Reconstr Surg 1989;84;280-8.
30. Rosenbaum TJ, Sundt TM Jr. Thrombus formation and endothelial alterations in microarterial anastomoses. J Neurosurg 1977;47:430-41.
31. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86:385-91.
32. Ornberg RL, Deune EG, Ozbek MR, Wun TC, Khouri RK. Localization of topically applied TFPI binding sites in an intimectomized microvessel. Thromb Haemost 1995;73:55-8.